Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

Shanyinde M, Girardi E, Puoti M, De Luca A, Sighinolfi L, Caterina UF, Caramello P, Lampe FC, D'Arminio Monforte A, Cozzi-Lepri A; ICONA Foundation Study Group.

BMC Public Health. 2019 Oct 15;19(1):1291. doi: 10.1186/s12889-019-7608-1.

2.

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.

Taramasso L, Lorenzini P, Di Biagio A, Lichtner M, Marchetti G, Rossotti R, Lapadula G, Cozzi-Lepri A, Vichi F, Antinori A, Bonora S, d'Arminio Monforte A; ICONA Foundation Study Group .

J Antimicrob Chemother. 2019 Nov 1;74(11):3295-3304. doi: 10.1093/jac/dkz353.

PMID:
31504633
3.

Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study.

Leone S, Lorenzini P, Cozzi-Lepri A, Orofino G, Bernacchia D, Castagna A, Menozzi M, Guaraldi G, Madeddu G, Di Biagio A, Puoti M, Gori A, d'Arminio Monforte A; ICONA Foundation Study Group.

Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1857-1865. doi: 10.1007/s10096-019-03618-8. Epub 2019 Jun 22.

PMID:
31230205
4.

Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.

Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group .

J Antimicrob Chemother. 2019 Sep 1;74(9):2732-2741. doi: 10.1093/jac/dkz237.

PMID:
31173639
5.

Is the rate of virological failure to cART continuing to decline in recent calendar years?

Rusconi S, Santoro MM, Gianotti N, Antinori A, Bonora S, Cingolani A, Ceccherini Silberstein F, Tavelli A, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group.

J Clin Virol. 2019 Jul;116:23-28. doi: 10.1016/j.jcv.2019.04.009. Epub 2019 May 3.

6.

The identification of pathogens associated with periprosthetic joint infection in two-stage revision.

Cozzi Lepri A, Del Prete A, Soderi S, Innocenti M, Civinini R.

Eur Rev Med Pharmacol Sci. 2019 Apr;23(2 Suppl):101-116. doi: 10.26355/eurrev_201904_17480.

7.

Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.

Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group.

Antivir Ther. 2019 Apr 12. doi: 10.3851/IMP3309. [Epub ahead of print]

PMID:
30977466
8.

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.

d'Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, Marchetti G, Lo Caputo S, Rusconi S, Gianotti N, Mazzotta V, Mazzarello G, Costantini A, Castagna A, Antinori A; ICONA Foundation Study Group.

J Antimicrob Chemother. 2019 May 1;74(5):1363-1367. doi: 10.1093/jac/dky566.

PMID:
30698801
9.

Total Knee Arthroplasty in Patients With Extra-Articular Deformity: Restoration of Mechanical Alignment Using Accelerometer-Based Navigation System.

Matassi F, Cozzi Lepri A, Innocenti M, Zanna L, Civinini R, Innocenti M.

J Arthroplasty. 2019 Apr;34(4):676-681. doi: 10.1016/j.arth.2018.12.042. Epub 2019 Jan 5.

PMID:
30685259
10.

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.

Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group.

J Int AIDS Soc. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227.

11.

Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014.

d'Arminio Monforte A, Diaz-Cuervo H, De Luca A, Maggiolo F, Cingolani A, Bonora S, Castagna A, Girardi E, Antinori A, Lo Caputo S, Guaraldi G, Cozzi-Lepri A; ICONA Foundation Study Group.

HIV Med. 2019 Feb;20(2):99-109. doi: 10.1111/hiv.12683. Epub 2018 Nov 21.

PMID:
30461158
12.

Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.

Dentone C, Di Biagio A, Cozzi Lepri A, Fenoglio D, Filaci G, Lichtner M, Carrara S, Giacometti A, Sighinolfi L, Marchetti G, Antinori A, D'arminio Monforte A; ICONA Foundation Study Group.

HIV Clin Trials. 2018 Aug;19(4):158-162. doi: 10.1080/15284336.2018.1488453. Epub 2018 Nov 13.

PMID:
30422095
13.

The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy.

Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sonnerborg A, Ruiz L, Monno L, Di Giambenedetto S, Gori A, Lapadula G; European Transmitted Drug Resistance collaboration (EU-TDR).

AIDS. 2019 Feb 1;33(2):315-326. doi: 10.1097/QAD.0000000000002046.

PMID:
30325769
14.

The anterior-based muscle-sparing approach to the hip: the "other" anterior approach to the hip.

Civinini R, Cozzi Lepri A, Carulli C, Matassi F, Villano M, Innocenti M.

Int Orthop. 2019 Jan;43(1):47-53. doi: 10.1007/s00264-018-4190-6. Epub 2018 Oct 4.

PMID:
30284607
15.

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART.

Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group.

J Antimicrob Chemother. 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350.

16.

First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.

Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group.

HIV Med. 2018 May 30. doi: 10.1111/hiv.12628. [Epub ahead of print]

PMID:
29846042
17.

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study.

Mussini C, Lorenzini P, Cozzi-Lepri A, Marchetti G, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group.

BMC Med. 2018 May 29;16(1):79. doi: 10.1186/s12916-018-1046-2.

18.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic.

Simonsen L, Higgs E, Taylor RJ, Wentworth D, Cozzi-Lepri A, Pett S, Dwyer DE, Davey R, Lynfield R, Losso M, Morales K, Glesby MJ, Weckx J, Carey D, Lane C, Lundgren J; INSIGHT FLU002 and FLU003 Study Groups.

Clin Infect Dis. 2018 Jul 18;67(3):341-349. doi: 10.1093/cid/ciy088.

19.

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy.

Ruggiero A, Cozzi-Lepri A, Beloukas A, Richman D, Khoo S, Phillips A, Geretti AM; ERAS Study Group.

Open Forum Infect Dis. 2018 Feb 3;5(2):ofy032. doi: 10.1093/ofid/ofy032. eCollection 2018 Feb.

20.

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort<sup/>.

d'Arminio Monforte A, Lorenzini P, Cozzi-Lepri A, Mussini C, Castagna A, Baldelli F, Puoti M, Vichi F, Maddaloni A, Lo Caputo S, Gianotti N, Antinori A; the Icona Foundation Study Group.

HIV Clin Trials. 2018 Apr;19(2):52-60. doi: 10.1080/15284336.2018.1440691. Epub 2018 Mar 1.

PMID:
29493419
21.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group.

HIV Med. 2018 May;19(5):324-338. doi: 10.1111/hiv.12581. Epub 2018 Feb 1.

PMID:
29388732
22.

Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial.

Itenov TS, Johansen ME, Bestle M, Thormar K, Hein L, Gyldensted L, Lindhardt A, Christensen H, Estrup S, Pedersen HP, Harmon M, Soni UK, Perez-Protto S, Wesche N, Skram U, Petersen JA, Mohr T, Waldau T, Poulsen LM, Strange D, Juffermans NP, Sessler DI, Tønnesen E, Møller K, Kristensen DK, Cozzi-Lepri A, Lundgren JD, Jensen JU; Cooling and Surviving Septic Shock (CASS) Trial Collaboration.

Lancet Respir Med. 2018 Mar;6(3):183-192. doi: 10.1016/S2213-2600(18)30004-3. Epub 2018 Jan 8.

PMID:
29325753
23.

HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients.

Saracino A, Cozzi-Lepri A, Shanyinde M, Ceccherini Silberstein F, Nozza S, Di Biagio A, Cassola G, Bruno G, Capobianchi M, Puoti M, Monno L, d'Arminio Monforte A; ICONA Foundation Study.

PLoS One. 2018 Jan 11;13(1):e0190302. doi: 10.1371/journal.pone.0190302. eCollection 2018.

24.

Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study.

Leone S, Shanyinde M, Cozzi Lepri A, Lampe FC, Caramello P, Costantini A, Giacometti A, De Luca A, Cingolani A, Ceccherini Silberstein F, Puoti M, Gori A, d'Arminio Monforte A; ICONA Foundation Cohort Study.

Eur J Clin Microbiol Infect Dis. 2018 May;37(5):871-881. doi: 10.1007/s10096-017-3180-8. Epub 2018 Jan 9.

PMID:
29318459
25.

Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015.

Dwyer DE, Lynfield R, Losso MH, Davey RT, Cozzi-Lepri A, Wentworth D, Uyeki TM, Gordin F, Angus B, Qvist T, Emery S, Lundgren J, Neaton JD; INSIGHT Influenza Study Group .

Open Forum Infect Dis. 2017 Oct 7;4(4):ofx212. doi: 10.1093/ofid/ofx212. eCollection 2017 Fall.

26.

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort.

Nozza S, Cozzi-Lepri A, Bai F, Rusconi S, Gori A, Cinque P, Ammassari A, Caramello P, Tambussi G, D'Arminio Monforte A, Marchetti G; Icona Foundation Study Group.

PLoS One. 2017 Dec 5;12(12):e0189045. doi: 10.1371/journal.pone.0189045. eCollection 2017.

27.

Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population.

Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, Hohaus S, Bandera A, Alba L, Galizzi N, Castagna A, D'arminio Monforte A, Antinori A; ICONA Foundation Study group.

PLoS One. 2017 Oct 31;12(10):e0186549. doi: 10.1371/journal.pone.0186549. eCollection 2017.

28.

Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study.

Smit M, Cassidy R, Cozzi-Lepri A, Quiros-Roldan E, Girardi E, Mammone A, Antinori A, Saracino A, Bai F, Rusconi S, Magnani G, Castelli F, Hsue P, d'Arminio Monforte A, Hallett TB.

PLoS One. 2017 Oct 23;12(10):e0186638. doi: 10.1371/journal.pone.0186638. eCollection 2017.

29.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group.

HIV Med. 2018 Feb;19(2):102-117. doi: 10.1111/hiv.12557. Epub 2017 Oct 6.

30.

Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression.

Gianotti N, Marchetti G, Antinori A, Saracino A, Gori A, Rizzardini G, Lichtner M, Bandera A, Mussini C, Girardi E, dʼArminio Monforte A, Cozzi-Lepri A.

J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):417-422. doi: 10.1097/QAI.0000000000001522.

PMID:
28816721
31.

Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015.

Rossetti B, Bai F, Tavelli A, Galli M, Antinori A, Castelli F, Pellizzer G, Cozzi-Lepri A, Bonora S, Monforte AD, Puoti M, De Luca A; ICONA Foundation study group.

Clin Microbiol Infect. 2018 Apr;24(4):422-427. doi: 10.1016/j.cmi.2017.07.021. Epub 2017 Jul 29.

32.

The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.

Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM, Post FA, Hill T, Kirk O, Pozniak A, Nelson M, Tostevin A, Dunn D, Lundgren J, Cozzi-Lepri A.

Antivir Ther. 2018;23(2):105-116. doi: 10.3851/IMP3178.

PMID:
28627486
33.

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.

d'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, Cingolani A, Tavelli A, Shanyinde M, Gori A, Girardi E, Andreoni M, Antinori A, Puoti M; Icona Foundation and HepaIcona Study Group.

PLoS One. 2017 May 17;12(5):e0177402. doi: 10.1371/journal.pone.0177402. eCollection 2017.

34.

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group.

Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5.

PMID:
28477212
35.

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.

Gianotti N, Cozzi-Lepri A, Antinori A, Castagna A, De Luca A, Celesia BM, Galli M, Mussini C, Pinnetti C, Spagnuolo V, d'Arminio Monforte A, Ceccherini-Silberstein F, Andreoni M; Icona Foundation Study and mono-PI/r database Study Cohorts.

PLoS One. 2017 Feb 13;12(2):e0171611. doi: 10.1371/journal.pone.0171611. eCollection 2017.

36.

Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death.

Casadellà M, Cozzi-Lepri A, Phillips A, Noguera-Julian M, Bickel M, Sedlacek D, Zilmer K, Clotet B, Lundgren JD, Paredes R; EuroSIDA in EuroCOORD.

PLoS One. 2017 Jan 27;12(1):e0166613. doi: 10.1371/journal.pone.0166613. eCollection 2017.

37.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group.

Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4. doi: 10.1016/j.cmi.2016.12.003. Epub 2016 Dec 9.

38.

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.

Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K, Maltez F, Beniowski M, Vullo V, Hassoun G, Kuzovatova E, Szlavik J, Kuznetsova A, Stellbrink HJ, Duvivier C, Edwards S, Laut K, Paredes R; EuroSIDA Study.

Medicine (Baltimore). 2016 Oct;95(40):e5020.

39.

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.

Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, Antinori A, Galli M, Di Perri G, Viale P, d'Arminio Monforte A, Gori A; ICONA Foundation Study Group.

PLoS One. 2016 Oct 7;11(10):e0160761. doi: 10.1371/journal.pone.0160761. eCollection 2016.

40.

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe.

Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D, Sabin C, van Sighem A, Ledergerber B, Torti C, Mocroft A, Podzamczer D, Dorrucci M, De Wit S, Obel N, Dabis F, Cozzi-Lepri A, García F, Brockmeyer NH, Warszawski J, Gonzalez-Tome MI, Mussini C, Touloumi G, Zangerle R, Ghosn J, Castagna A, Fätkenheuer G, Stephan C, Meyer L, Campbell MA, Chene G, Phillips A; Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

HIV Med. 2017 Mar;18(3):171-180. doi: 10.1111/hiv.12411. Epub 2016 Sep 14.

41.

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort.

d'Arminio Monforte A, Cozzi-Lepri A, Maggiolo F, Rizzardini G, Manconi PE, Gianotti N, Quirino T, Pinnetti C, Rusconi S, De Luca A, Antinori A; Icona Foundation Study cohort.

PLoS One. 2016 Jun 27;11(6):e0156360. doi: 10.1371/journal.pone.0156360. eCollection 2016.

42.

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group.

J Antimicrob Chemother. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185. Epub 2016 Jun 5.

PMID:
27272727
43.

Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.

Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, Cohen CJ, Phillips A, Lundgren JD, Neaton JD; INSIGHT SMART/ESPRIT/SILCAAT Study Group.

PLoS One. 2016 May 12;11(5):e0155100. doi: 10.1371/journal.pone.0155100. eCollection 2016.

44.

Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study.

Nasta P, Salmon D, d'Arminio Monforte A, Pimenta JM, Cerini C, Giralda M, Winnock M, Cozzi-Lepri A.

HIV Clin Trials. 2016 May;17(3):96-108. doi: 10.1080/15284336.2016.1150409. Epub 2016 Mar 16.

PMID:
27125364
45.

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.

Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, dʼArminio Monforte A; ICONA Foundation Study Group.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71. doi: 10.1097/QAI.0000000000000849.

46.

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord.

J Antimicrob Chemother. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28.

47.

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.

Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, John Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodríguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Pérez-Hoyos S, Jarrin I, Guest JL, D'Arminio Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernán MA; Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration.

Int J Epidemiol. 2016 Dec 1;45(6):2038-2049. doi: 10.1093/ije/dyv295.

48.

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.

Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group.

PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015.

49.
50.

During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.

Ruggiero A, De Spiegelaere W, Cozzi-Lepri A, Kiselinova M, Pollakis G, Beloukas A, Vandekerckhove L, Strain M, Richman D, Phillips A, Geretti AM; ERAS Study Group.

EBioMedicine. 2015 Jul 21;2(9):1153-9. doi: 10.1016/j.ebiom.2015.07.025. eCollection 2015 Sep.

Supplemental Content

Loading ...
Support Center